Medical Devices: Page 102


  • Medtronic's FDA approval sets up fight for recharge-free pain market

    The medtech sees Vanta helping it gain share in a market it has struggled to penetrate in the past. Abbott Laboratories, Boston Scientific and specialist spinal cord stimulation rival Nevro are also competing.

    By June 11, 2021
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell/MedTech Dive
    Image attribution tooltip

    FDA lays out device cybersecurity efforts as feds look to implement Biden executive order

    The president signed an order last month seeking to bolster the nation's cyber posture amid growing threats from hackers. 

    By June 9, 2021
  • the FDA Headquarters Explore the Trendline
    Image attribution tooltip
    Sara Silbiger via Getty Images
    Image attribution tooltip
    Trendline

    Top 5 stories from MedTech Dive

    From haphazard layoffs at the Food and Drug Administration to the industry’s current IPO environment and tracking FDA-authorized AI devices, here is a collection of top stories from MedTech Dive.

    By MedTech Dive staff
  • Medtronic's HVAD controversy

    Medtronic's HeartWare HVAD ending brings questions about $1B acquisition

    Nearly five years after Medtronic's buy of HeartWare International, the medtech giant pulled the flagship product of the deal due to safety risks, ceding the market to rival Abbott.

    By June 8, 2021
  • Image attribution tooltip
    Medtronic
    Image attribution tooltip

    Medtronic lands FDA approval for brain stimulation leads it expects to drive share gains

    CEO Geoff Martha has boasted the nod for SenSight will help it close "a key competitive gap." The medtech competes with Abbott and Boston Scientific in the market. 

    By June 8, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Cancer tech dominates FDA's latest batch of breakthrough devices

    The agency's recent breakthrough designations feature a clutch of oncology devices and diagnostics from companies including Viome and Avenda Health.

    By June 7, 2021
  • Nick Jonas, Dexcom
    Image attribution tooltip
    Courtesy of Dexcom, Nick Jonas Super Bowl kit
    Image attribution tooltip

    Dexcom shares clinical data on G7 CGM ahead of next-gen showdown with Abbott

    The results compare favorably to data on Abbott’s Libre 2, further setting the stage for the release of one of the most anticipated new products of 2021 in the diabetes tech market.

    By June 4, 2021
  • Medtronic's HVAD controversy

    Medtronic pulls HeartWare HVAD pump from market amid recalls, patient deaths

    The medtech said the move was influenced by growing evidence the system had higher mortality risks than comparable devices. FDA advised providers to use Abbott's HeartMate 3 as an alternative.

    By June 3, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA warns device makers of falsified records at Italian ethylene oxide sterilization facilities

    BD and Medtronic are among those that already recalled products processed by Steril Milano, accused by the agency of falsifying graphs and parameters of sterilization certificates for a variety of products dating back to 2016.

    By June 3, 2021
  • Abiomed buys preCARDIA to bag breakthrough heart failure device

    William Blair analysts had hopes the buy could help Abiomed move past "two years of commercial disruptions" to drive long-term growth.

    By June 2, 2021
  • Image attribution tooltip

    iRhythm Technologies

    Image attribution tooltip

    Amid pricing tumult, iRhythm CEO resigns after 4 months in office

    After taking over on Jan. 12, Mike Coyle stepped down Tuesday. CFO Douglas Devine will assume the role amid a search for a permanent replacement. Shares were down by nearly 17% Wednesday morning.

    By June 2, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA seeks 8% budget boost for CDRH to back resurgence of domestic device production

    The Biden administration said its request for the Center for Devices and Radiological Health will help the U.S. reduce reliance on products from China and other countries and strengthen its ability to respond to emergencies.

    By June 1, 2021
  • Swiss medtech sounds alarm as MDR erects barriers to EU market

    The Swiss Medical Technology Association said the change will cost the industry it represents the equivalent of $126 million to meet new administrative requirements.

    By May 28, 2021
  • Image attribution tooltip
    Medtronic
    Image attribution tooltip

    Medtronic steps up robotics bet as its challenger to Intuitive starts clinical trial

    The medtech giant seeks to double or triple sales in its 2023 fiscal year. However, analysts warned that near-term investments will pressure margins in the short term.

    By May 28, 2021
  • Image attribution tooltip
    Joe Raedle via Getty Images
    Image attribution tooltip

    Rising hospital ransomware attacks could endanger patients, hit bottom lines hard, Moody's says

    Systems have been rendered more vulnerable due to COVID-19 as more non-clinical employees work from home. The warning echos comments made recently by the FDA's cyber chief for medical devices. 

    By Ron Shinkman • May 27, 2021
  • Analysts tip Edwards' US TAVR growth at 90% in April

    A Jefferies review of hospital data suggests the medtech could comfortably beat the current analyst growth forecast, but comes with multiple caveats.

    By May 27, 2021
  • Medtronic revenue up 37% as electives make a comeback

    CEO Geoff Martha told investors Thursday most businesses are returning to near pre-COVID-19 growth rates, though he admitted there is "work to do" in areas like neurovascular and diabetes.

    By May 27, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA draft guidances lay out postmarket medical device data requirements

    Building on existing policy, one proposal deals with rules for Class II and III products while another relates to PMAs. 

    By May 27, 2021
  • MDR challenges remain as regulation goes into effect: MedTech Europe

    The European trade group contends that while the Medical Device Regulation's May 26 effective date marks a significant milestone, hurdles limit industry’s ability to "seamlessly supply certified devices under the new rules."  

    By May 26, 2021
  • Senate confirms Chiquita Brooks-LaSure as head of CMS

    AdvaMed and MDMA both called out the Medicare Coverage of Innovative Technology rule, now delayed, as a priority for the new administrator. President Joe Biden has yet to name an FDA chief.

    By Rebecca Pifer • May 25, 2021
  • Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip

    Ransomware, other cyber threats mount as medtech industry tries to adapt

    "Everything is hackable," said Kevin Fu, the FDA's medical device cybersecurity chief, who noted that ransomware in particular can render a device useless. 

    By May 25, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA clears 2 endoscopes that avoid reprocessing

    The agency, which has urged a shift to endoscopes with single-use parts or that are fully disposable, gave the OK to UroViu to market a single-use cytoscope and to China's EndoFresh for a disposable digestive endoscopy system.

    By May 25, 2021
  • MDR is live. Here are 5 things to know on where the rule stands.

    The device industry has resolved some near term pressures as the EU's delayed landmark regulation comes into effect, but challenges related to IVDR, Brexit and more remain.

    By May 25, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Boston Scientific recalls venous stents because of migration risk

    The medtech giant is recalling all Vici SDS and Vici RDS stent systems distributed over a 30-month period after receiving 17 complaints. The FDA categorized it as a Class I recall, its most serious designation.

    By May 24, 2021
  • Biden orders Software Bill of Materials to boost cybersecurity. AdvaMed wants uniform standards.

    An executive order calls for an electronically readable way to provide an inventory of third-party components in devices. The medtech lobby backs the idea but says standardization is critical.  

    By May 21, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA seeks feedback on device ingredient labeling requirements

    The agency held a public meeting late in 2019 debating adding more specific information on materials used in devices with long-term exposure such as breast implants and metal-on-metal hips.

    By May 21, 2021